- PLN41.58m
- PLN36.06m
- PLN12.85m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 13.13 | ||
| Price to Tang. Book | 13.13 | ||
| Price to Free Cashflow | 207 | ||
| Price to Sales | 3.24 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -6.18% | ||
| Return on Equity | -27.17% | ||
| Operating Margin | -6.32% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | PLNm | 6.07 | 6.45 | 7.24 | 10.15 | 12.85 | n/a | n/a | 25.64% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | -89.16 | +463.55 | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Read Gene SA is a Poland-based company primarily engaged in the biotechnology sector. The Company is focused on research and technologies which aim is to detect, prevent and treat malignant tumors. The company's main segments are chemoprevention, clinical trials and genetic testing which are complementary to each other. Chemoprevention involves the use of natural or synthetic substances to inhibit, reverse or delay the process of cancer and in order to achieve that, the Company distributes supplements and food with products with a controlled content of micronutrients and vitamins. The Company provides clinical trials and offers them to corporate clients, mainly from the medical, pharmaceutical, chemical and biotechnology industries. The Company is also offering genetic testing services, including early lung cancer detection test, breast cancer test, colorectal cancer test or prostate cancer risk test.
Directors
- Bronislaw Ziemianin CSU
- Jan Lubinski CMG (65)
- Tomasz Huzarski VSU
- Cezary Cybulski OTH (63)
- Karolina Ertmanska OTH
- Adam Gliszczynski SUB
- Jacek Gronwald SUB
- Janusz Pirog SUB
- Adam Szuba SUB
- Dariusz Wiecaszek SUB
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 27th, 2005
- Public Since
- February 12th, 2009
- No. of Employees
- 11
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Warsaw Stock Exchange- Shares in Issue
- 9,449,731
- Address
- Grzepnica, ul. Alabastrowa 8, SZCZECIN, 72-003
- Web
- https://read-gene.com/
- Phone
- +48 914334256
- Contact
- Monika Ewert-Krzemieniewska
- Auditors
- Firma Audytorsko – Konsultingowa „PER SALDO" Spólka z o.o
Upcoming Events for RDG
Similar to RDG
Bioton SA
Warsaw Stock Exchange
Braster SA
Warsaw Stock Exchange
Captor Therapeutics SA
Warsaw Stock Exchange
Genomed SA
Warsaw Stock Exchange
Genomtec SA
Warsaw Stock Exchange
FAQ
As of Today at 22:52 UTC, shares in Read Gene SA are trading at PLN4.40. This share price information is delayed by 15 minutes.
Shares in Read Gene SA last closed at PLN4.40 and the price had moved by -20.58% over the past 365 days. In terms of relative price strength the Read Gene SA share price has underperformed the FTSE Global All Cap Index by -22.57% over the past year.
There is no consensus recommendation for this security.
Find out moreRead Gene SA does not currently pay a dividend.
Read Gene SA does not currently pay a dividend.
Read Gene SA does not currently pay a dividend.
To buy shares in Read Gene SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of PLN4.40, shares in Read Gene SA had a market capitalisation of PLN41.58m.
Here are the trading details for Read Gene SA:
- Country of listing: Poland
- Exchange: WSE
- Ticker Symbol: RDG
Based on an overall assessment of its quality, value and momentum Read Gene SA is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Read Gene SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -11.23%.
As of the last closing price of PLN4.40, shares in Read Gene SA were trading -12.27% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Read Gene SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at PLN4.40.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Read Gene SA's management team is headed by:
- Bronislaw Ziemianin - CSU
- Jan Lubinski - CMG
- Tomasz Huzarski - VSU
- Cezary Cybulski - OTH
- Karolina Ertmanska - OTH
- Adam Gliszczynski - SUB
- Jacek Gronwald - SUB
- Janusz Pirog - SUB
- Adam Szuba - SUB
- Dariusz Wiecaszek - SUB